Fundraising Fox
Karyopharm Therapeutics
Newton, US · Founded 2008 · 4 known investors
Find your way into Karyopharm Therapeutics
Sign up to see every warm intro you have to Karyopharm Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Karyopharm Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Karyopharm is a pharmaceutical company developing drugs based on its SINE (Selective Inhibitor of Nuclear Export) technology, with medicines targeting cancers including multiple myeloma and diffuse large B-cell lymphoma. It serves patients and healthcare providers in oncology.
Founders & leadership
SP
Stuart PoultonExecutiveStuart Poulton is Executive Vice President and Chief Development Officer at Karyopharm Therapeutics, overseeing global clinical development operations. He previously led strategic portfolio management at AbbVie and brings experience spanning drug development across oncology, bone health, cardiovascular, diabetes, anti-infectives, immunology, and neuroscience throughout his pharmaceutical industry career.
RR
Reshma RangwalaExecutiveRangwala holds an MD with specialization in medical oncology and a doctorate in cell biology/neurosciences, with extensive clinical development experience in oncology and immunology spanning multiple cancer indications including lung, hepatocellular, ovarian, and melanoma, as well as expertise in immunotherapy, companion diagnostics, and regulatory interactions with health agencies.
RP
Richard PaulsonCEORichard Paulson has spent over 25 years in the life sciences industry in various roles across global organizations. He serves as Executive Officer and Director at Karyopharm, a pharmaceutical company developing SINE technology-based medicines for oncology indications including multiple myeloma and diffuse large B-cell lymphoma.
PH
Peter HonigNamed on SEC filing
CS
Chen SchorNamed on SEC filing
Board
DR
Deepika R. PakianathanBoard director
BE
Barry E. GreeneBoard director
MR
Mansoor Raza MirzaBoard director
GG
Garen G. BohlinBoard director
Investors · 4
Avoro Capital Advisorslisted by Avoro Capital AdvisorsNew York
How we know: Avoro Capital Advisors's portfolio page · Not right? Tell us
Foresite Capitallisted by Foresite CapitalWest Hollywood
How we know: Foresite Capital's portfolio page · Not right? Tell us
HEALTHCARE ROYALTY PARTNERSlisted by HEALTHCARE ROYALTY PARTNERSNew York
How we know: HEALTHCARE ROYALTY PARTNERS's portfolio page · Not right? Tell us
RA CapitalreportedBoston
How we know: investing.com · funding news · Not right? Tell us
Funding
SEC filings, press & company announcements$165M disclosed across 1 of 3 rounds · 2011–2026
▶$165MraisedDec 2022 · 33 investors · PharmaceuticalsRule 506(b)
▶$165MraisedDec 2022 · 33 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Peter HonigDirector
- Barry E. GreeneDirector
- Stuart PoultonExecutive Officer
- Michael ManoExecutive Officer
- Reshma RangwalaExecutive Officer
- Richard PaulsonExecutive Officer, Director
- Deepika R. PakianathanDirector
- Chen SchorDirector
- Stephen MitchenerExecutive Officer
- Michael MasonExecutive Officer
- Mansoor Raza MirzaDirector
- Garen G. BohlinDirector
- Christy J. OligerDirector
- Sohanya ChengExecutive Officer
- Offering amount
- $165M
- Amount sold
- $165M
- Sales commissions
- $9.9M
- Placement agents
- Robert W. Baird & Co. Incorporated, Piper Sandler & Co., Jefferies LLC, Barclays Capital, Inc., H.C. Wainwright & Co. LLC
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Kite PharmaKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.
Companies working in the same space as Karyopharm Therapeutics.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Karyopharm Therapeutics do?
- Karyopharm is a pharmaceutical company developing drugs based on its SINE (Selective Inhibitor of Nuclear Export) technology, with medicines targeting cancers including multiple myeloma and diffuse large B-cell lymphoma. It serves patients and healthcare providers in oncology.
- Who are Karyopharm Therapeutics's investors?
- Karyopharm Therapeutics's investors include Avoro Capital Advisors, Foresite Capital, HEALTHCARE ROYALTY PARTNERS, RA Capital.
- How much funding has Karyopharm Therapeutics raised?
- Karyopharm Therapeutics has disclosed $165M raised across 1 of its 3 known rounds.
- Where is Karyopharm Therapeutics headquartered?
- Karyopharm Therapeutics is headquartered in Newton, US.